Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder

INTRODUCTION: Current treatments for overactive bladder (OAB) are often discontinued due to side effects or lack of efficacy. The goal of this study was to determine if combining a phosphodiesterase type 4 inhibitor (PDE4i); with a type 5 inhibitor (PDE5i); would have a beneficial effect on OAB symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Balog, Brian M., Tangada, Abhilasha, Sheth, Pooja, Song, Qi-Xiang, Couri, Bruna M., Porras, Leah L., Deng, Gary G., Damaser, Margot S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713339/
https://www.ncbi.nlm.nih.gov/pubmed/31461445
http://dx.doi.org/10.1371/journal.pone.0220788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713339/
https://www.ncbi.nlm.nih.gov/pubmed/31461445
http://dx.doi.org/10.1371/journal.pone.0220788

Ejemplares similares